EP Patent

EP4013404A1 — Methods of treating cancer

Assigned to F Hoffmann La Roche AG · Expires 2022-06-22 · 4y expired

What this patent protects

Provided herein are methods of treating cancer in a patient in need thereof includes administering to the patient a therapeutically effective amount of entrectinib wherein the patient has impaired hepatic function and methods of managing adverse reactions of administration of ent…

USPTO Abstract

Provided herein are methods of treating cancer in a patient in need thereof includes administering to the patient a therapeutically effective amount of entrectinib wherein the patient has impaired hepatic function and methods of managing adverse reactions of administration of entrectinib in a patient.

Drugs covered by this patent

Patent Metadata

Patent number
EP4013404A1
Jurisdiction
EP
Classification
Expires
2022-06-22
Drug substance claim
No
Drug product claim
No
Assignee
F Hoffmann La Roche AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.